Ivan Maillard Named Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center

Ivan Maillard, MD, PhD, has been appointed Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

A physician-scientist, Dr. Maillard is a practicing hematologist-oncologist with expertise in treating lymphoma and leukemia. His research focuses on hematopoiesis, bone marrow transplantation, Notch signaling, and lymphoid biology, areas in which he has made significant contributions to understanding the underlying mechanisms of hematologic cancers and developing potential therapeutic strategies.

Dr. Ivan Maillard joins Memorial Sloan Kettering Cancer Center (MSK) from the University of Pennsylvania, where he most recently held the position of Kevin Reitnauer Fox Professor in Oncology. Since 2018, he served as Vice-Chief for Research in the Division of Hematology/Oncology, Department of Medicine, and was an investigator with the Abramson Family Cancer Research Institute. Additionally, Dr. Maillard was the Co-Scientific Director of the University of Pennsylvania’s Cell Therapy and Transplantation Program.

Dr. Ivan Maillard is originally from Lausanne, Switzerland. He obtained his PhD training from the University of Lausanne and the Swiss Academy of Medical Sciences, and his MD training from both the University of Lausanne and the University of Zurich, Switzerland. Following his medical education, Dr. Maillard completed residency training at the University of Lausanne and fellowship training in Hematology/Oncology at the University of Pennsylvania.

In 2007, he joined the University of Michigan’s Life Sciences Institute and Division of Hematology/Oncology, where he launched and developed an independent research program that has been continuously funded by the National Institutes of Health (NIH) since 2011. In addition to his research, Dr. Maillard held a clinical role focused on lymphoma care and led the University of Michigan’s leukemia program from 2014 to 2017.

Dr. Maillard’s career has been marked by his dual focus on cutting-edge research and clinical care, with a particular emphasis on hematopoiesis, hematologic malignancies, and innovative therapeutic approaches. His work has positioned him as a leader in the field, making significant contributions to our understanding of blood cancers and advancing potential treatments for patients.

About Memorial Sloan Kettering Cancer Center

The Sloan-Kettering Institute for Cancer Research (SKI) was established on August 8, 1945, with a $4 million gift from Alfred P. Sloan, Jr., Chairman of General Motors, and a co-founding role played by engineer and inventor Charles F. Kettering. Kettering, known for his innovations in automotive technology, served on SKI’s Committee on Scientific Policy and helped shape the institute’s vision. The initial funding allowed for the construction of SKI and covered its early operational costs. From the outset, the institute was conceived as a research-driven entity focused exclusively on scientific inquiry into cancer, with the goal of advancing both understanding and treatment of the disease.

SKI was designed to be a key intellectual pillar of Memorial Sloan Kettering Cancer Center (MSK), contributing to its mission of cancer care through groundbreaking research. Its emphasis on scientific discovery quickly attracted top researchers and became central to MSK’s rise as a leader in cancer biology. SKI’s early work laid the groundwork for many of the advances in cancer treatment and research that would follow, helping establish Memorial Sloan Kettering as one of the world’s leading institutions in the fight against cancer.

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: to end cancer for life. MSK’s specialized care teams deliver personalized, compassionate, and expert care to patients of all ages, ensuring that each individual receives the most effective treatment tailored to their needs.

Informed by groundbreaking basic research conducted at the Sloan Kettering Institute, MSK scientists collaborate across disciplines to conduct innovative translational and clinical research. This research is driving a revolution in our understanding of cancer as a disease, while also improving our ability to prevent, diagnose, and treat it.

For more information, visit oncodaily.com.